Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway

Shine Gwo Shiah, Shuang En Chuang, Yat Pang Chau, Shing Chuan Shen, Min Liang Kuo

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

β-Lapachone (β-Lap) has been found to inhibit DNA topoisomerases (Topos) by a mechanism distinct from that of other commonly known Topo inhibitors. Here, we demonstrated a pronounced elevation of H2O2 and O2 - in human leukemia HL-60 cells treated with β-Lap. Treatment with other Topo poisons, such as camptothecin (CPT), VP-16, and GL331, did not have the same effect. On the other hand, antioxidant vitamin C (Vit C) treatment effectively antagonized β-Lap-induced apoptosis. This suggested that a reactive oxygen species (ROS)-related pathway was involved in β-Lap-induced apoptosis program. We also found that c-Jun NH2-terminal kinase (JNK) but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2 was persistently activated in apoptosis induced by β-Lap. Overexpression of a dominant-negative mutant mitogen-activated protein kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide or Vit C all prevented β-Lap-induced JNK activation and the subsequent apoptosis. Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, VP-16, or GL331. These results confirm again that ROS acts as a mediator for JNK activation during β-Lap-induced apoptosis. Furthermore, we found that β-Lap can stimulate CPP32/Yama activity, which was, however, markedly inhibited by the MEKK1-DN expression or Vit C treatment. Again, CPT-induced CPP32/Yama activation can be abolished by MEKK1-DN but not by Vit C treatment. Taken together, these results indicate that β-Lap but not other Topo inhibitors triggers apoptosis signaling, i.e., JNK and subsequent CPP32/Yama activation are mediated by the generation of ROS.

Original languageEnglish
Pages (from-to)391-398
Number of pages8
JournalCancer Research
Volume59
Issue number2
Publication statusPublished - Jan 16 1999
Externally publishedYes

Fingerprint

Topoisomerase Inhibitors
JNK Mitogen-Activated Protein Kinases
Ascorbic Acid
Apoptosis
Camptothecin
Reactive Oxygen Species
Mitogen-Activated Protein Kinase 1
Etoposide
DNA Topoisomerases
Mitogen-Activated Protein Kinase 3
Antisense Oligonucleotides
Poisons
HL-60 Cells
p38 Mitogen-Activated Protein Kinases
Leukemia
Antioxidants

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway. / Shiah, Shine Gwo; Chuang, Shuang En; Chau, Yat Pang; Shen, Shing Chuan; Kuo, Min Liang.

In: Cancer Research, Vol. 59, No. 2, 16.01.1999, p. 391-398.

Research output: Contribution to journalArticle

@article{4fbef6b1cc914d889f0fba9b27b5742b,
title = "Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway",
abstract = "β-Lapachone (β-Lap) has been found to inhibit DNA topoisomerases (Topos) by a mechanism distinct from that of other commonly known Topo inhibitors. Here, we demonstrated a pronounced elevation of H2O2 and O2 - in human leukemia HL-60 cells treated with β-Lap. Treatment with other Topo poisons, such as camptothecin (CPT), VP-16, and GL331, did not have the same effect. On the other hand, antioxidant vitamin C (Vit C) treatment effectively antagonized β-Lap-induced apoptosis. This suggested that a reactive oxygen species (ROS)-related pathway was involved in β-Lap-induced apoptosis program. We also found that c-Jun NH2-terminal kinase (JNK) but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2 was persistently activated in apoptosis induced by β-Lap. Overexpression of a dominant-negative mutant mitogen-activated protein kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide or Vit C all prevented β-Lap-induced JNK activation and the subsequent apoptosis. Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, VP-16, or GL331. These results confirm again that ROS acts as a mediator for JNK activation during β-Lap-induced apoptosis. Furthermore, we found that β-Lap can stimulate CPP32/Yama activity, which was, however, markedly inhibited by the MEKK1-DN expression or Vit C treatment. Again, CPT-induced CPP32/Yama activation can be abolished by MEKK1-DN but not by Vit C treatment. Taken together, these results indicate that β-Lap but not other Topo inhibitors triggers apoptosis signaling, i.e., JNK and subsequent CPP32/Yama activation are mediated by the generation of ROS.",
author = "Shiah, {Shine Gwo} and Chuang, {Shuang En} and Chau, {Yat Pang} and Shen, {Shing Chuan} and Kuo, {Min Liang}",
year = "1999",
month = "1",
day = "16",
language = "English",
volume = "59",
pages = "391--398",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway

AU - Shiah, Shine Gwo

AU - Chuang, Shuang En

AU - Chau, Yat Pang

AU - Shen, Shing Chuan

AU - Kuo, Min Liang

PY - 1999/1/16

Y1 - 1999/1/16

N2 - β-Lapachone (β-Lap) has been found to inhibit DNA topoisomerases (Topos) by a mechanism distinct from that of other commonly known Topo inhibitors. Here, we demonstrated a pronounced elevation of H2O2 and O2 - in human leukemia HL-60 cells treated with β-Lap. Treatment with other Topo poisons, such as camptothecin (CPT), VP-16, and GL331, did not have the same effect. On the other hand, antioxidant vitamin C (Vit C) treatment effectively antagonized β-Lap-induced apoptosis. This suggested that a reactive oxygen species (ROS)-related pathway was involved in β-Lap-induced apoptosis program. We also found that c-Jun NH2-terminal kinase (JNK) but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2 was persistently activated in apoptosis induced by β-Lap. Overexpression of a dominant-negative mutant mitogen-activated protein kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide or Vit C all prevented β-Lap-induced JNK activation and the subsequent apoptosis. Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, VP-16, or GL331. These results confirm again that ROS acts as a mediator for JNK activation during β-Lap-induced apoptosis. Furthermore, we found that β-Lap can stimulate CPP32/Yama activity, which was, however, markedly inhibited by the MEKK1-DN expression or Vit C treatment. Again, CPT-induced CPP32/Yama activation can be abolished by MEKK1-DN but not by Vit C treatment. Taken together, these results indicate that β-Lap but not other Topo inhibitors triggers apoptosis signaling, i.e., JNK and subsequent CPP32/Yama activation are mediated by the generation of ROS.

AB - β-Lapachone (β-Lap) has been found to inhibit DNA topoisomerases (Topos) by a mechanism distinct from that of other commonly known Topo inhibitors. Here, we demonstrated a pronounced elevation of H2O2 and O2 - in human leukemia HL-60 cells treated with β-Lap. Treatment with other Topo poisons, such as camptothecin (CPT), VP-16, and GL331, did not have the same effect. On the other hand, antioxidant vitamin C (Vit C) treatment effectively antagonized β-Lap-induced apoptosis. This suggested that a reactive oxygen species (ROS)-related pathway was involved in β-Lap-induced apoptosis program. We also found that c-Jun NH2-terminal kinase (JNK) but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2 was persistently activated in apoptosis induced by β-Lap. Overexpression of a dominant-negative mutant mitogen-activated protein kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide or Vit C all prevented β-Lap-induced JNK activation and the subsequent apoptosis. Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, VP-16, or GL331. These results confirm again that ROS acts as a mediator for JNK activation during β-Lap-induced apoptosis. Furthermore, we found that β-Lap can stimulate CPP32/Yama activity, which was, however, markedly inhibited by the MEKK1-DN expression or Vit C treatment. Again, CPT-induced CPP32/Yama activation can be abolished by MEKK1-DN but not by Vit C treatment. Taken together, these results indicate that β-Lap but not other Topo inhibitors triggers apoptosis signaling, i.e., JNK and subsequent CPP32/Yama activation are mediated by the generation of ROS.

UR - http://www.scopus.com/inward/record.url?scp=0033556233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033556233&partnerID=8YFLogxK

M3 - Article

C2 - 9927052

AN - SCOPUS:0033556233

VL - 59

SP - 391

EP - 398

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -